Merck KGaA spinoff licenses IBD drug to Eisai joint venture by Nick Paul Taylor Friday, March 31, 2017 Merck KGaA spinoff Calypso Biotech has licensed its inflammatory bowel disease candidate to EA Pharma, a joint venture between Eisai and Ajinomoto.
